$PTN: Three rare obesity indications. Two IND submissions on the calendar. One drug target that a $6.5 billion company keeps validating. What most investors skip over is the specific problem Palatin is trying to solve. Rhythm's setmelanotide is the commercial benchmark for MC4R agonism. It works. But it causes hyperpigmentation. In a therapy meant for rare genetic disorders where patients are often children and adherence spans years, visible skin darkening is not a cosmetic footnote. It shapes prescriber conversations, patient willingness to stay on drug, and quality of life over time. bioreview.com/a-new-obesity-… Palatin's entire design thesis targets that exact gap. Its next-generation injectable peptide and oral candidates are engineered for high MC4R selectivity while minimizing MC1R activity, the receptor pathway responsible for pigmentation changes. The company reports substantially improved selectivity over earlier compounds. Preclinical data does not guarantee clinical outcomes, but it defines the bet being placed. The injectable peptide IND in Q4 2026 is the first regulatory marker. The release after that one will tell investors whether the tolerability signal that looked good in preclinical models is real enough to justify Phase 1 dose escalation. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Palatin Technologies, Inc. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Japan's export headline of 17% YoY looks impressive. But volume growth was just 0.5%. Almost all of it is yen weakness and energy price inflation. Middle East crude imports collapsed 62% in volume as the Strait of Hormuz closure hit hard. The AI/semiconductor boom is doing the heavy lifting masking what's actually a fragile trade picture. And now the BoJ is expected to hike 25bps this month anyway. reuters.com/world/asia-pacif…

$EMAT: what does it actually take to build a credible, non-China rare earth magnet supply chain? Eighteen years of commercial production in Korea, customers including Ford, Hyundai, and Samsung, $100 million in fresh financing, 13 ULVAC furnaces on order, and a board that includes a former U.S. Acting Secretary of Defense. thefinanceherald.com/evoluti… January 1, 2027 is when DFARS 252.225-7052 locks every U.S. defense contractor out of Chinese magnets in qualifying weapons systems. Not a target. A statutory date. Every defense prime in the country is running that clock, and the peer group of Western rare earth magnet producers on NASDAQ remains thin: MP Materials, USA Rare Earth, Critical Metals, and EMAT. By EMAT's own SEC-filed characterization, it is the only one outside China with proven, real-world operational expertise producing high-performance sintered magnets at commercial scale today. The 13 ULVAC machines ordered May 14 are targeted to lift nameplate capacity to 10,000 metric tons per year, including 6,000 metric tons of high-performance sintered grades. MP Materials' Fort Worth facility, backed by the Pentagon with more than $400 million, is designed for roughly 1,000 metric tons annually. The scale difference on paper is substantial. Full build-out to EMAT's nameplate target requires multi-year execution, financing, and permitting. The real gate: whether EMAT's Korean-qualified magnet grades clear defense prime DFARS compliance procedures and generate actual defense contracts. That qualification process is the step between hardware on order and revenue in hand, and it is the read that matters. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Evolution Metals & Technologies Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Nvidia Raises $25 Billion in Bonds, Its Largest Debt Deal, Betting on Decades of AI Growth techtimes.com/articles/31846…

Two decades of defense leadership covers a lot of ground. In Yiftach Kleinman's case, it covers the Iron Dome and Trophy APS program ecosystem at Rafael Advanced Defense Systems, followed by the CEO chair at SpearUAV, the AI-driven loitering munition company that was acquired by UVision in late 2025. Duke Robotics just named him its incoming chief executive, effective no later than September 8, 2026. globenewswire.com/news-relea… $DUKR is three months into Nasdaq trading, fresh off a $9.2 million uplisting raise. It has a weapons drone system, the Bird of Prey, marketed by Elbit and confirmed in active IDF operational deployment. It has a commercial IC Drone service that began its 2026 season with Israel Electric Corporation, targeting over $1 million in revenue. It has AEROTRACE, an AI infrastructure intelligence platform launched in February. What the company did not have was executive credibility in the defense procurement world at the level that creates real pipeline. Kleinman was a Colonel in the IDF active reserve, managed acquisitions and board seats across Rafael's subsidiary network, ran international defense deal campaigns in the US, Europe, and Asia Pacific, and took SpearUAV through production scale into a full exit. That is the profile now stepping into the CEO seat. Outgoing CEO Yossef Balucka stays on as President to advance commercial operations. The dual-track structure lets Duke pursue both trajectories without sacrificing either. The next major signal from this leadership structure will be whether the defense pipeline shows new activity in the quarters following Kleinman's start date. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Duke Robotics Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

June 15, 2026. One of the largest interconnect manufacturers in the U.S. moved $QTEX's AME system onto its production floor at 97% yield. That sentence does not require explanation. It is the sentence. Let me unpack what 97% yield actually means here. QTREX's AME platform prints complex 3D monolithic structures that integrate conductive materials, RF dielectrics, shielding, and thermal management into a single engineered unit. The manufacturer ran hundreds of evaluations covering reliability, vibration, environmental exposure, humidity, and assembly integration before this result. globenewswire.com/news-relea… Quantum computing's interconnect problem is structural: every dilution refrigerator eventually becomes a cable-management crisis as qubit counts climb. QTREX prints that problem out of existence. The AME platform acquired from Nano Dimension for up to $12.5 million earlier this year is now running in production at a U.S. interconnect manufacturer with 97% yield. The next structural update to watch for is whether the advanced discussions with one of the top-5 global quantum computing companies advance to a signed definitive agreement. That signal would confirm QTREX as foundational across a leading platform's forward hardware roadmap. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. QTREX Quantum Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

In December 2025, Entera published first data showing a long-acting PTH analog could sustain calcium elevation for more than three days via the N-Tab oral platform. Six months later, at ENDO 2026, that finding has been reproduced in the TPTx rat, the minipig, and non-human primates, all with consistent results and no safety signals. $ENTX is making a systematic scientific argument: three independent preclinical models, three consistent outcomes. That kind of cross-species replication is what a regulatory agency looks for before granting an IND for first-in-human evaluation. globenewswire.com/news-relea… Hypoparathyroidism is a rare disease with limited treatment options and high dependency on daily subcutaneous injection. EB612's calcemic effect duration (approximately three days per dose in both minipig and NHP models) addresses the fundamental pharmacological challenge of delivering PTH orally: you need a long-acting analog because unmodified PTH(1-34) clears too rapidly through the gut absorption window to sustain a meaningful calcium response throughout the day. The next update to watch for is the IND submission confirmation: it will clarify whether the program advances to the clinic on the late 2026 timeline signaled today, and signal how regulators respond to the oral LA-PTH formulation strategy. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Entera Bio Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Exclusive: The US is using an Iranian smuggling tactic to sneak oil out of the Gulf DUBAI, June 16 (Reuters) - The United States military has overseen scores of secretive ship-to-ship oil transfers to keep Gulf energy exports flowing, using aerial and water drones as well as helicopters in an operation to guide convoys to awaiting tankers. The operation on the edge of the Strait of Hormuz employs a shuttling technique long used by Iran to skirt sanctions. Two specific locations where the oil transfers take place were identified by 11 people familiar with the operation – one off the coast of Fujairah in the United Arab Emirates and the other off Oman’s port of Sohar. It started in early May, and at least 92 ships have been involved in the transfers, according to shipping data and satellite imagery reviewed by Reuters. reuters.com/business/energy/… As recently as June 11, 17 pairs of ships could be seen carrying out simultaneous oil transfers at the two sites, according to satellite images ‌reviewed by Reuters

The Fed meets tomorrow and the script has completely flipped. A year ago markets were pricing in multiple cuts. Now BofA expects the FOMC to drop its easing bias entirely, and some policymakers may pencil in hikes. PPI running at 6.5% YoY, core PPI at 5.1%, CPI at 4.2%. Chair Warsh will try to thread the needle by blaming supply shocks and pointing to AI disinflation. Good luck with that. economicweekly.substack.com/…

Six grades. Two Tier-1 OEMs. Commercial-scale production running in Korea right now. $EMAT just posted the certification milestone that most non-China rare earth magnet suppliers can only put on a roadmap. The grades span the full performance spectrum: N48M and N50M for medium-temperature applications, N42H and N45H for high-temperature industrial and EV uses, and the heavy rare earth-containing N35SH and N46SH for EV traction motors, wind turbines, robotics actuators, and defense systems. That last category is where supply concentration is most acute. China's April 2025 and October 2025 export controls specifically targeted the dysprosium that goes into those grades. globenewswire.com/news-relea… May 14: binding purchase orders placed with ULVAC for 13 of the world's leading sintered magnet production machines, with delivery and installation scheduled November 2026. That expands annual capacity to approximately 10,000 metric tons. The January 1, 2027 DFARS deadline restricting Chinese-origin rare earth magnets in U.S. defense systems is the deadline the whole supply chain is racing toward. The read that matters: Tier-1 OEM certification is the gate. The next phase is whether it converts into binding supply contracts for the U.S. defense industrial base before January 2027. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Evolution Metals & Technologies Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

After reading the last ten Entera Bio press releases, what stands out about today’s ENDO 2026 data is how methodically this company has built its case. July 2025: FDA agrees in writing that BMD is an acceptable Phase 3 primary endpoint. September 2025: ASBMR data shows Phase 2 EB613 improved both trabecular and cortical bone after just six months, with cortical gains comparable to injectable teriparatide. March 2026: full Phase 3 protocol submitted to FDA. April 2026: BVF Partners puts $10 million behind the program. What you don’t usually see in this space: a company that actually simplified its formulation going into Phase 3. Usually the Phase 3 candidate is more complex than the earlier-stage version. Entera went from a multi-tablet format in Phase 2 to a single tablet for Phase 3, and today’s Phase 1 bridging data confirms the single tablet carries the same PK/PD properties forward. globenewswire.com/news-relea… The clinical story for $ENTX is built on a 505(b)(2) regulatory pathway that references FDA’s existing approval of Forteo® (teriparatide, approved 2002 for postmenopausal osteoporosis). The mechanism is not being proved from scratch. What Phase 3 must demonstrate is that the oral tablet produces the same BMD effect that Phase 2 suggested and that the teriparatide literature supports. Comparable PK to Forteo® is a prerequisite for that argument, and today’s data delivers it. The Phase 3 readout on total hip, lumbar spine, and femoral neck BMD at 12 months is the data that determines whether EB613 becomes the first oral anabolic for osteoporosis. That is the read that matters for this entire program. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Entera Bio Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

What separates a defense drone company with a real technology moat from one that is just assembling off-the-shelf hardware? In a contested electromagnetic environment where radio-frequency signals are jammed or denied, the answer comes down to the sensing and communication layer. $QUCY just licensed that layer. globenewswire.com/news-relea… The June 11, 2026 IP License Agreement with Project LightShift, Inc. grants Quantum Cyber exclusive worldwide rights to the patent-protected quantum photonic array technology. The system uses nano multi-spectrum lenses and controllable diode lasers in a nearest-neighbor configuration to transmit and receive multi-frequency photonic signals, verified using Near Field Quantum electrodynamics principles. Manufacturing methods under development combine self-assembly and epitaxial growth. Wolf Kohn, PhD, Chief Scientist of Project LightShift, invented the technology. Management describes this as the quantum computing coordination layer of its System-of-Systems platform, the capability that separates Quantum Cyber from conventional autonomous defense integrators. The counter-UAS market is projected to grow from $3.1 billion to $10.6 billion by 2030 at a 27.2 percent compound annual growth rate. In a market expanding at that pace, exclusive worldwide rights to a frequency-agile photonic sensing and communication layer for drone platforms either forms the foundation of a product line or defines the ceiling on what this company becomes. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Quantum Cyber N.V. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Oil down 4.4% this morning on the US-Iran Strait of Hormuz deal. But here's the catch: the strait doesn't actually reopen until mines are cleared over the next 30 days, and the FT is already flagging a multi-week shipping backlog. The market is pricing in the headline, not the logistics. 60-day ceasefire extension with nuclear talks still ahead. This is a truce, not a resolution. ft.com/content/76bed6e5-ab1f…

Inside a research suite at The Ohio State University Comprehensive Cancer Center, three patients with recurrent glioblastoma received an experimental intratumoral treatment between December 2025 and March 2026. As of the May 3 data cutoff, all three had achieved local disease control. Two showed complete responses. None had experienced local or distant recurrence. None had residual symptoms from the procedure. That data went to the FDA as a pre-specified interim safety report. On June 11, the agency returned its answer: proceed. globenewswire.com/news-relea… $DRTS is now cleared to enroll the final seven patients in the REGAIN trial and has been authorized to add two more leading U.S. academic cancer centers to the study. Alpha Tau Medical Ltd. first secured FDA clearance to begin this trial in 2025, following Breakthrough Device Designation in October 2021 and acceptance into the FDA's prestigious Total Product Life Cycle Advisory Program in October 2024. Glioblastoma strikes roughly 14,000 Americans each year, and median survival after recurrence is typically only a matter of months. Against that backdrop, a 100% local disease control rate and 67% complete response rate in three consecutive patients, with a manageable safety profile and zero unanticipated serious adverse events, represents a signal that neuro-oncologists have clearly taken notice of. The company intends to resume patient recruitment immediately. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Alpha Tau Medical Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Everyone's focused on when Hormuz reopens. The real question is what happens after. OPEC's share of global oil production just hit an all-time low of 22%. The UAE already quit the group. And every revenue-starved member will race to flood the market the moment the strait clears. Saudi Arabia spent the war rerouting exports through the Red Sea. That makes it nearly impossible to now tell Iraq and Kuwait to hold back. A 5M bpd surplus could be waiting on the other side of peace. reuters.com/commentary/reute…

When was the last time you saw a microcap defense company voluntarily close a stock sale program it barely used because it genuinely did not need the money? That is exactly what $QUCY just did. Quantum Cyber N.V. terminated its at-the-market facility with Maxim Group LLC on June 7, 2026, citing a debt-free balance sheet and over $15 million in cash from warrant exercises completed the prior month. The ATM had existed since October 2025. It went unused for the entire two months before termination. With all prior debt extinguished and no exercisable warrants remaining on the cap table, the company simply determined the facility served no further purpose. globenewswire.com/news-relea… The cash will now go toward executing a strategic pipeline that is already in motion. An LOI is active to acquire a 43,000-square-foot Connecticut manufacturing facility through subsidiary Quantum Drones Corporation. An Advanced Filament Manufacturing Division is being established to produce the company's patented EMP-hardened composite 3D printing material for an 80-printer drone production farm, with the company stating no domestic competitor offers comparable broadband EMP/EMI shielding in an FDM-compatible commercial format. Patent prosecution is ongoing across solid rocket motor propulsion, quantum swarm navigation for autonomous ground vehicles, and counter-UAS architectures. The picture being assembled here is a vertically integrated autonomous defense manufacturer, and with $15 million on hand and no dilution vehicle in sight, it appears to be moving forward on its own terms. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Quantum Cyber N.V. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Every anabolic osteoporosis treatment on the market today requires a needle. Entera Bio Ltd. has spent years building the case that a daily pill can do the same job, and on June 14 in Chicago, that case gets its most prominent platform yet. $ENTX announced that new clinical data for EB613, its oral PTH(1-34) tablet for postmenopausal osteoporosis, was selected for a Late-Breaking Oral Presentation at ENDO 2026, the Endocrine Society's annual meeting (June 13-16, Chicago). The abstract title says plainly what the data is meant to demonstrate: that the single EB613 tablet is the final formulation candidate for a planned Phase 3 study. Two additional pipeline programs also earned accepted slots at the same conference: EB612, Entera's oral long-acting PTH tablet for hypoparathyroidism, and EB618, its oral dual GLP-1/glucagon tablet targeting obesity and metabolic disorders. The clinical record behind EB613 has accumulated carefully. A Phase 2 study in 161 postmenopausal women met all bone turnover biomarker and BMD endpoints. Data presented at ASBMR 2025 showed EB613 produced significant improvements in both trabecular and cortical bone after just six months, with cortical gains comparable to injectable teriparatide. In July 2025, the FDA agreed that bone mineral density, not fracture incidence, could serve as the primary Phase 3 endpoint, a meaningful shift from the standard that had kept the osteoporosis drug space dormant for close to a decade. A complete Phase 3 protocol was submitted to FDA in March 2026. A Phase 1 bridging study in January 2026 confirmed the single-tablet formulation. BVF Partners invested $10 million in April 2026 to help fund Phase 3 initiation, and Entera reported $20.4 million in cash as of May 2026, sufficient through Q1 2027. One in two women over 50 will suffer an osteoporotic fracture in their lifetime. No new drug has been approved for the disease since 2019. globenewswire.com/news-relea… _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Entera Bio Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

The US govt says 7M barrels/day are now flowing out of the Persian Gulf. Chevron's CEO says "not quite that much." Meanwhile, the SPR just hit its lowest level since 1983 — drained by 66M barrels since the Iran war began. Markets are calm for now, but the insurance is running out. If flows don't normalize by summer, the price spike gets delayed, not avoided. $CVX fortune.com/2026/06/12/u-s-e…

Trump's Iran war closed the Strait of Hormuz and sent oil prices surging. The unintended winner? China's cleantech industry. $BYD auto exports hit a record 900k units in April. Yadea scooter demand up 70% YoY. A Sany exec literally said "We have to thank Trump." When energy disruption accelerates the EV transition, it deepens the world's dependence on Chinese supply chains. The geopolitical irony is hard to miss. ft.com/content/12d0d1e4-d08c…

China's factory-gate prices just hit a nearly 4-year high, up 3.9% YoY in May. But here's the catch: it's not a demand story. It's an energy shock from the Iran war closing the Strait of Hormuz, plus AI-driven input costs. Meanwhile CPI is flat at 1.2%, credit is contracting, and car sales are down 22%. Upstream inflation with downstream deflation. Margin squeeze for most Chinese manufacturers is real. finance.yahoo.com/economy/po…